Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer
New cancer findings from University of California published
October 23rd, 2008
"The enzyme mTOR ( mammalian target of rapamycin) is a major target for therapeutic intervention to treat many human diseases, including cancer, but very little is known about the processes that control levels of mTOR protein," scientists in the United States report. "Here, we show that mTOR is targeted for ubiquitination and consequent degradation by binding to the tumor suppressor protein FBXW7. Human breast cancer cell lines and primary tumors showed a reciprocal relation between loss of FBXW7 and deletion or mutation of PTEN ( phosphatase and tensin homolog), which also activates mTOR," wrote J.H. Mao and colleagues, University of California. The...
Source: Women's Health Weekly (2008-10-23)
|
